丁苯酞联合阿托伐他汀应用于急性脑梗死患者中的效果分析

Effect analysis of butylphthalide combined with atorvastatin in patients with acute cerebral infarction

目的探讨丁苯酞联合阿托伐他汀应用于急性脑梗死(ACI)患者中的效果。方法92例ACI患者,按照随机数字表法分为对照组与研究组,各46例。对照组采用阿托伐他汀治疗,研究组在对照组基础上联合应用丁苯酞治疗。对比两组疗效,治疗前后的神经损伤标志物[神经元特异性烯醇化酶(NSE)、同型半胱氨酸(Hcy)]、血清炎症因子[白细胞介素-6(IL-6)、C反应蛋白(CRP)]、凝血功能指标[凝血酶原时间(PT)、纤维蛋白原(FIB)],不良反应发生情况。结果研究组治疗总有效率93.48%高于对照组的73.91%,差异有统计学意义(P<0.05)。治疗2周,研究组NSE(13.52±3.50)μg/L、Hcy(12.05±1.45)mmol/L均低于对照组的(17.47±4.03)μg/L、(16.85±1.90)mmol/L,差异有统计学意义(P<0.05)。治疗2周,研究组IL-6(48.02±8.98)pg/ml、CRP(6.80±1.89)mg/L低于对照组的(58.65±7.90)pg/ml、(11.50±2.00)mg/L,差异有统计学意义(P<0.05)。治疗2周,研究组PT(13.02±1.42)s长于对照组的(10.56±1.54)s,FIB(2.50±0.45)g/L低于对照组的(3.75±0.50)g/L,差异有统计学意义(P<0.05)。两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论丁苯酞联合阿托伐他汀治疗ACI效果确切,能够有效调节神经损伤标志物与血清炎症因子,改善神经功能与凝血功能,安全性较佳,具有临床推广价值。

Objective To discuss the effect of butylphthalide combined with atorvastatin in patients with acute cerebral infarction(ACI).Methods A total of 92 ACI patients were divided into a control group and a research group according to the random numerical table,with 46 cases in each group.The control group was treated with atorvastatin,and the research group was treated with butylphthalide on the basis of the control group.Both groups were compared in terms of efficacy,markers of nerve injury[neuron-specific enolase(NSE),homocysteine(Hcy)],serum inflammatory factors[interleukin-6(IL-6),C-reactive protein(CRP)],coagulation indexes[prothrombin time(PT),fibrinogen(FIB)]before and after treatment,and the occurrence of adverse reactions.Results The total effective rate of treatment in the research group was 93.48%,which was higher than 73.91%in the control group,and the difference was statistically significant(P<0.05).At 2 weeks of treatment,the NSE(13.52±3.50)μg/L and Hcy(12.05±1.45)mmol/L in the research group were lower than(17.47±4.03)μg/L and(16.85±1.90)mmol/L in the control group,and the differences were statistically significant(P<0.05).At 2 weeks of treatment,the IL-6(48.02±8.98)pg/ml and CRP(6.80±1.89)mg/L in the research group were lower than(58.65±7.90)pg/ml and(11.50±2.00)mg/L in the control group,and the differences were statistically significant(P<0.05).At 2 weeks of treatment,the PT(13.02±1.42)s in the research group was longer than(10.56±1.54)s in the control group,and FIB(2.50±0.45)g/L was lower than(3.75±0.50)g/L in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of butylphthalide and atorvastatin has a definite effect in the treatment of ACI,and can effectively regulate the markers of nerve injury and serum inflammatory factors,improve the nerve function and blood coagulation function.It has high safety,and the value of clinical promotion.